bearish

M3 Inc

M3 4Q Results: Earnings Miss and Further Slowdown Seems Unavoidable

402 Views30 Apr 2024 01:57
As we expected, m3 missed its own guidance as well as consensus estimates. Medical Platform's earnings growth has decelerated, and the completion of Covid related projects have impacted overseas biz.
What is covered in the Full Insight:
  • 4QFY03/2024 Results Highlights
  • Medical Platform: Both Revenue and OP Drop YoY
  • Evidence Solution: Order Backlog Declines
  • Overseas Business: US Clinical Trial Business Books an Impairment Loss
  • Outlook and Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
x